Double-Negative Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis.

Neurol Neuroimmunol NeuroinflammJul 17, 2026 (epub)
Clinical ResearchNeurologyOpen access

Antonio Malvaso, Francesca Bovis, Giacomo Greco et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined double-negative neuromyelitis optica spectrum disorder (DN-NMOSD) in 671 patients, comparing it to AQP4-NMOSD and MOGAD. The study found that 73.6% of DN-NMOSD patients relapsed, with a mean annualized relapse rate of 1.08. Maintenance immunosuppression significantly reduced relapse rates (pooled rate ratio 0.19).

Key findings

  • 73.6% of patients with DN-NMOSD experienced relapses.
  • Mean annualized relapse rate was 1.08 in DN-NMOSD compared to 0.84 in AQP4-NMOSD.
  • Maintenance immunosuppression led to a significant reduction in relapse rate (pooled rate ratio 0.19).
  • No significant change in disability was observed in DN-NMOSD post-treatment.

Why it matters

Understanding the clinical spectrum and treatment response in DN-NMOSD is crucial for improving management strategies. The high relapse rate highlights the need for effective early intervention to prevent disability.

Source

PubMed · PMID 42468026Free full text on PubMed Central

Published in Neurol Neuroimmunol Neuroinflamm. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.